Cargando...
Emerging agents for the treatment of metastatic urothelial cancer
Over the past few decades, platinum-based combination chemotherapy (PBCC) has been the preferred initial therapy for metastatic urothelial cancer (mUC). However, despite a response rate of approximately 50%, a small proportion of patients with distant metastases may be cured by cisplatin-based combi...
Guardado en:
| Publicado en: | Investig Clin Urol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
The Korean Urological Association
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100010/ https://ncbi.nlm.nih.gov/pubmed/33943047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.20200597 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|